Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of gender and anchor drugs on TDF renal toxicity.
Quiros-Roldan E, Amadasi S, Paraninfo G, Izzo I, Allegri R, Motta D, Gatti F, Cristini G, Carosi G, Mendeni M, Torti C. Quiros-Roldan E, et al. Among authors: motta d. J Acquir Immune Defic Syndr. 2010 Oct;55(2):e11-2. doi: 10.1097/QAI.0b013e3181ef7930. J Acquir Immune Defic Syndr. 2010. PMID: 20859083 No abstract available.
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Albini L, Cesana BM, Motta D, Focà E, Gotti D, Calabresi A, Izzo I, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Quiros-Roldan E, Manili L, Guaraldi G, Lapadula G, Torti C. Albini L, et al. Among authors: motta d. J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):18-30. doi: 10.1097/QAI.0b013e31823a6124. J Acquir Immune Defic Syndr. 2012. PMID: 21992924 Clinical Trial.
Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.
Focà E, Motta D, Borderi M, Gotti D, Albini L, Calabresi A, Izzo I, Bellagamba R, Narciso P, Sighinolfi L, Clò A, Gibellini D, Quiros-Roldan E, Brianese N, Cesana BM, Re MC, Torti C. Focà E, et al. Among authors: motta d. BMC Infect Dis. 2012 Feb 14;12:38. doi: 10.1186/1471-2334-12-38. BMC Infect Dis. 2012. PMID: 22333484 Free PMC article. Clinical Trial.
Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Caputo SL, Sighinolfi L, Ladisa N, El-Hamad I, Quiros-Roldan E, Frank I. Torti C, et al. Among authors: motta d. Clin Microbiol Infect. 2012 May;18(5):449-58. doi: 10.1111/j.1469-0691.2011.03650.x. Epub 2011 Sep 15. Clin Microbiol Infect. 2012. PMID: 21919996 Free article. Clinical Trial.
Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir.
Gotti D, Cesana BM, Albini L, Calabresi A, Izzo I, Focà E, Motta D, Bellagamba R, Fezza R, Narciso P, Sighinolfi L, Maggi P, Brianese N, Quiros-Roldan E, Guaraldi G, Torti C. Gotti D, et al. Among authors: motta d. HIV Clin Trials. 2012 Sep-Oct;13(5):245-55. doi: 10.1310/hct1305-245. HIV Clin Trials. 2012. PMID: 23134625
Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received.
Motta D, Brianese N, Focà E, Nasta P, Maggiolo F, Fabbiani M, Cologni G, Di Giambenedetto S, Di Pietro M, Ladisa N, Sighinolfi L, Costarelli S, Castelnuovo F, Torti C. Motta D, et al. AIDS Res Ther. 2012 Jun 15;9(1):18. doi: 10.1186/1742-6405-9-18. AIDS Res Ther. 2012. PMID: 22703595 Free PMC article.
114 results